

Your contact

Markus Kaiser

Tel. +49 (0)6151 72-2031

## Press release

September 6, 2010

### Merck Expands Parateck<sup>®</sup> Range with Parateck<sup>®</sup> Mg DC

- **Directly compressible magnesium salt excipient**
- **Can be used without additional binders, ideal for solid dosage forms**
- **Meets all food and pharmaceutical purity requirements**

Darmstadt, September 6, 2010 – Merck KGaA announced today that it will be introducing Parateck<sup>®</sup> Mg DC, the latest addition to its Parateck<sup>®</sup> Functional Particle Engineering concept, at the CPhI Worldwide in Paris from October 5 -7, 2010. Like all Parateck<sup>®</sup> products, this special magnesium salt is ideally suited as a specialty excipient for solid dosage forms such as tablets, capsules and powders. The special feature: Parateck<sup>®</sup> Mg DC is directly compressible without the need for any binders. This means it is much simpler to manufacture end products since various process steps can be dispensed with. Far fewer ingredients require declaration compared with the previous Mg-containing tablets.

#### Large surface – far-reaching effect

Parateck<sup>®</sup> Mg DC is the first pure magnesium hydroxide carbonate on the market that makes it possible to compress high-quality tablets directly without the need for binders. A unique particle morphology is one of its outstanding properties. Thanks to its exceptional particle structure and large BET surface, it is readily compressible, and a brilliant adsorbent. Formulators can produce small, hard tablets with very high Mg concentrations — a feature that offers tremendous advantages in many conventional formulations. For example, the magnesium concentration of various



## Press release

antacids or mineral and food supplements often exceeds 40%. The use of Parateck<sup>®</sup> Mg DC also eliminates the need for various process steps during production as direct compressibility means no extra granulation is required. Parateck<sup>®</sup> Mg DC – an all-round success in terms of both functionality and economic efficiency!

Parateck<sup>®</sup> Mg DC is the latest achievement made possible by the Merck Functional Particle Engineering concept. It meets all the applicable purity requirements in the food and pharmaceutical sectors. Pharmacopoeia declarations are available and the EMPROVE<sup>®</sup> dossier is expected to be ready as of 2011.

### **The Parateck<sup>®</sup> range is certain to ensure success**

Merck offers a range of highly effective functional excipients under the Parateck<sup>®</sup> brand name. Its brilliant reactivity, and consequently its success, are attributable to the Functional Particle Engineering concept. In addition to the newest product Parateck<sup>®</sup> Mg DC, Parateck<sup>®</sup> delta M (mannitol), Parateck<sup>®</sup> M (directly compressible mannitol), Parateck<sup>®</sup> SI (directly compressible sorbitol) Parateck<sup>®</sup> ODT and Parateck<sup>®</sup> LUB (various lubricants) are already on the market.

All Merck press releases are distributed via e-mail at the same time they become available on the Merck website: Please go to <http://www.merck.de/newsabo> to register online, change your selection or discontinue this service.

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.